International nephrology societies advise against nonsteroidal anti-inflammatory drug (NSAID) use in patients with hypertension, heart failure, or chronic kidney disease (CKD); however, recent studies have not investigated the frequency or associations of use in these patients.
N onsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed and effective for the treatment of musculoskeletal pain [1] [2] [3] [4] [5] [6] ; however, NSAID use is associated with increased risk of cardiovascular and renal complications, including hypertension, edema, myocardial infarction, and impaired renal function, particularly in patients with a history of cardiovascular or renal disease.
4,7-12 Consequently, international nephrology societies have released recommendations via their respective national Choosing Wisely campaigns against NSAID use in individuals with hypertension, heart failure, or chronic kidney disease (CKD). 13,14 While these recommendations offer basic analgesics and nonpharmacological treatments as preferable alternatives, 13,14 it is both possible and disconcerting that some physicians might instead prescribe opioids, which typically pose elevated risk of adverse events and dependence vs NSAIDs.
15
Despite the above considerations when managing musculoskeletal pain, the frequency of NSAID use and its subsequent clinical association with short-term complications among high-risk patients is not well understood. Although a study 16 of large, US commercial claims databases estimated that
NSAIDs were used for musculoskeletal pain management in 14.4% to 16.2% of high-risk patients, estimates were limited to the insurance plan level. Therefore, as with prior studies, prescribing patterns among individual physicians, as well as the patient and physician characteristics associated with NSAID use, were not investigated. In addition, although prior research [17] [18] [19] [20] has examined cardiac and renal complications in high-risk patients receiving NSAIDs, this association has not been assessed in a real-world population to our knowledge. We see the latter point as critically important given the relative benefit of NSAIDs to manage musculoskeletal pain and the potentially harmful associations of other pain management therapies, such as opioids. The present study aimed to estimate the frequency of and variation in prescription NSAID use among primary care patients with hypertension, heart failure, or CKD in Ontario, Canada, over time and by physician. Our secondary objectives were to identify patient and physician characteristics associated with prescription NSAID use and to explore its potential association with acute cardiovascular and renal complications.
Methods

Design, Setting, and Participants
We conducted a retrospective cohort study using populationbased administrative health care databases linked via unique encoded identifiers and analyzed at the Institute for Clinical Evaluative Sciences in Toronto, Ontario, Canada. We identified Ontario Health Insurance Plan (OHIP) claims indicating visits to a primary care physician (general practitioner or family physician) for a musculoskeletal disorder (eg, fractures/ dislocations, strains/sprains, arthritis, and related conditions), assessed using 3-digit OHIP diagnostic codes (1 per claim), between April 1, 2012, and March 31, 2016, in Ontario, Canada 16, 21 (eTable 1 in the Supplement). Only visits involving
Ontario residents 65 years and older with a valid provincial health card number were eligible to ensure that patients' prescription drug costs were covered, at least in part, under the Ontario Drug Benefit (ODB) program. Long-term care residents and patients with missing sex or postal code were excluded. Patients were required to have a diagnosis of hypertension, heart failure, or CKD within 365 days before their visit, assessed using International Classification of Diseases and Related Health Problems, Tenth Revision, Canada (ICD-10-CA) codes in National Ambulatory Care Reporting System and Discharge Abstract Database claims, as well as OHIP diagnostic codes contained within OHIP claims 16, [21] [22] [23] [24] [25] [26] (eTable 1 in the Supplement). Patients were included in the denominator for all quarters in which they had at least 1 eligible visit. 16 If patients had multiple visits per quarter, only their first visit was selected. The use of data in this project was authorized under §45 of Ontario's Personal Health Information Protection Act, which does not require review by a research ethics board.
Primary Outcome: Prescription NSAID Use
Prescription NSAID use was defined as at least 1 patient-level ODB claim for a prescription NSAID dispensing within 7 days after a visit (eTable 2 and eTable 3 in the Supplement). 27 Over-thecounter formulations that are paid for out of pocket are not captured in the ODB claims database and were consequently excluded from our study. 27 Aspirin and topical NSAID formulations were excluded because both are basic analgesics (along with acetaminophen and capsaicin) recommended as first-line treatment for pain management over other NSAIDs or opioids. 28 Furthermore, aspirin has low nephrotoxicity and is recommended for comorbid cardiovascular disease prevention.
4,29
Secondary Outcomes: Cardiovascular and Renal Safety
Multiple binary outcomes that might reflect short-term complications secondary to NSAID use, including exacerbation of preexisting heart and kidney disease, were observed up to 37 days after each visit. 13,14,30 Specifically, we captured whether patients (1) had a cardiac complication, defined as a hospitalization or emergency department visit with an ICD-10-CA code for cardiovascular disease (eg, hypertension, heart failure, hypertensive CKD, myocardial infarction, or stroke) [31] [32] [33] ; (2) had a renal complication, defined as a hospitalization with an ICD-10-CA or Canadian Classification of Health Interventions code indicating hyperkalemia, an acute kidney injury, or acute dialysis 23, 29, 34 ; or (3) had died, with their death recorded in the Registered Persons Database.
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Covariates Back pain and arthritis are the most frequently reported types of musculoskeletal pain among older adults and are associated with increased duration of NSAID use. Therefore, we recorded whether an eligible visit was for back pain, arthritis, or another type of musculoskeletal disorder. 36, 37 Prior NSAID and opioid use (excluding formulations with methadone hydrochloride or naloxone) were each defined as at least 1 ODB claim for a related drug within 90 days before a visit. 27, 29, 30, [38] [39] [40] We independently defined the use of reninangiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) and diuretics 30, [41] [42] [43] [44] [45] [46] as (1) current if a related drug was dispensed within 90 days before a visit and the amount supplied was enough to ensure coverage through the visit date plus 7 days (ie, ≥1 day of overlap with the primary outcome if observed); (2) recent if a claim was made in the past 90 days but the amount supplied did not overlap with the visit date plus 7 days; or (3) neither recent nor current if there was no related dispensing within 90 days before a visit. 28 We assumed that patients followed the recommended daily dose (ie, the number of days supplied equated with the number of days the drug was taken 
Statistical Analysis
Rates of prescription NSAID use were calculated by quarter and health system level-region (Local Health Integrated Network), practice, and physician-between fiscal years 2012-2013 and 2015-2016. Variation was described via interquartile ranges (IQRs).
Rates of prescription NSAID use over time were analyzed via negative binomial regression with quarter as a continuous independent variable, the aggregate number of visits resulting in prescription NSAID use as the dependent variable, and the log number of visits as an offset term. To account for seasonality, 3 indicator variables were created to represent the quarter in which a visit occurred irrespective of fiscal year.
A mixed-effects logistic regression was used to analyze patients' odds of prescription NSAID use, while adjusting for all patient-level, physician-level, and practice-level characteristics detailed under the covariates heading above. Practicespecific random effects were included to account for withinpractice correlation in prescribing behavior, which enabled calculation of the intracluster correlation coefficient and the median odds ratio. The latter is a measure of heterogeneity in practice-level prescribing behavior that is interpretable on the odds ratio scale. [50] [51] [52] Computational issues with the statistical software prohibited inclusion of random effects to account for within-physician correlation or patient-level repeated measures. Consequently, we limited our regression sample to 1 randomly selected visit per patient-all of which belonged to an identifiable practice and physician-to facilitate convergence without introducing temporal bias.
53,54
The association of prescription NSAID use (primary outcome) with experiencing a cardiovascular or renal safety-related outcome within 8 to 37 days after a visit (any secondary outcome) was investigated via a landmark analysis. Patients with any cardiovascular or renal safety-related outcome within 7 days (the landmark date) after their visit were excluded because they would be unlikely or unable to fill a prescription within that week. Patients with an opioid dispensing between 90 days before their visit and 37 days after their visit were excluded to ensure that observed outcomes were not attributable to prescribed opioid use.
28
Among the remaining patients, a mixed-effects logistic regression identical to the primary model (excluding the prior opioid use covariate) was used to identify patient-level probability of prescription NSAID use conditional on measured baseline covariates potentially associated with any secondary outcome and/ or prescription NSAID use. 55 Patients with prescription NSAID use (exposed) were then matched using greedy nearest-neighbor matching to a nonuser (unexposed) on the logit of their propensity score using calipers of width equal to 0.2 of the SD of the logit of the propensity score. [55] [56] [57] The propensity score model was iteratively modified until all comparisons of baseline characteristics between exposed and unexposed individuals had a standardized difference less than 0.10 (absolute value). 56 McNemar test for correlated binary proportions was used in the matched sample to assess whether exposed patients were more likely to experience any cardiovascular or renal safety-related outcome than unexposed patients. The association between prescription NSAID use and experience of a safety-related outcome was summarized as the absolute risk difference.
56,58
All analyses were performed using statistical software (SAS, version 9.4; SAS Institute Inc). Significance was assessed at 2-sided P ≤ .05.
Results
Cohort Characteristics
We identified 2 415 291 primary care visits for musculoskeletal disorders involving 814 049 older adult patients (mean [SD] age, 75.3 [4.0] years; 61.1% female) with hypertension, heart failure, or CKD ( Figure 1 ). Prescription NSAID use was observed after 224 825 visits (9.3%), with 79.6% of dispensing claims for traditional vs selective NSAIDs. 
Temporal Trends
Based on 2 415 291 visits, Figure 2 shows a declining trend in prescription NSAID use over time, with an absolute reduction of 2.1% between the first quarter (April to June 2012 
Variation by Health System Level
Prescription NSAID use ranged from 6.7% to 14.4% across 14 health regions (median, 8.4%; IQR, 7.3%-9.6%) and from 0.9% to 60.3% among 688 primary care practices (median, 10.1%; IQR, 6.3%-17.0%) (eFigure 1 and eFigure 2 in the Supplement). Figure 3 shows substantial variation in use among 7365 primary care physicians (range, 0.9%-69.2%; median, 11.0%; IQR, 6.7%-16.7%).
Characteristics Associated With Prescription NSAID Use Table 2 summarizes our primary mixed-effects regression results based on 532 163 patients ( Figure 1 ). Prescription NSAID use was observed in 9.0% of patients, with traditional NSAIDs (82.7%) more commonly dispensed than selective cyclooxygenase 2 inhibitors (18.3%). Histories of hypertension, back pain, arthritis, prior NSAID use, and renin-angiotensin inhibitor use were associated with increased odds of prescription a For all characteristics, P < .001. P values are not adjusted for correlation within practices or patients.
b Includes angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
c Characteristics are only provided for those primary care visits that involved a patient rostered to an identifiable physician and practice (n = 2 361 953).
d Represents the patient enrollment model, which informs practice organization and remuneration.
NSAID use. Conversely, patients with heart failure, CKD, or prior opioid use had reduced odds of prescription NSAID use. Physicians who were male, international medical graduates, or further removed from graduation had increased odds of prescribing an NSAID. The magnitude of the median odds ratio of 2.11 in Table 2 suggests that the unexplained heterogeneity between practices is of greater relevance than any measured characteristic except prior NSAID use (odds ratio, 2.79) for understanding an individual patient's odds of prescription NSAID use. The intracluster correlation coefficient indicates that 15.7% of the total variation in prescription NSAID use was attributable to practicelevel clustering.
Association of Prescription NSAID Use With Safety-Related Outcomes
Our sample of 35 552 matched patient pairs, each consisting of an exposed and nonexposed patient matched on the logit of their propensity score for prescription NSAID use (exposure), is summarized in eTable 4 in the Supplement. Only 16.8% of exposed patients used selective NSAIDs. 
Discussion
Among a large, Ontario-based cohort of primary care visits involving older adults with a musculoskeletal disorder and recent history of hypertension, heart failure, or CKD, we found that almost 10% resulted in prescription NSAID use despite patients' high risk for cardiovascular and renal complications. We observed widespread prescribing variation, up to 77-fold, among primary care practices and physicians and identified several patient, physician, and practice characteristics associated with NSAID use. We found that prescription NSAID use was not associated with significantly higher (or lower) risk of cardiovascular or renal safety-related outcomes. It has been previously established that prescription and over-the-counter NSAID use is common among patients with preexisting heart or kidney disease despite evidence-based recommendations against this practice.
13,14 One study 16 found that prescription NSAID use for musculoskeletal pain management ranged from 14.4% to 16.2% in patients with hypertension, heart failure, or CKD. A study 59 of patients with preexisting cardiovascular disease found that self-reported use of both prescription and over-the-counter NSAIDs was common, particularly among patients with angina or myocardial infarction. Another study 28 found that 5.7% of patients with moderate to severe CKD reported NSAID use; however, use was primarily driven by over-the-counter medications, and many of the patients were unaware of their condition. Our study adds to these prior investigations by demonstrating frequent prescription NSAID use among older adults at high risk for complications secondary to NSAID use. In addition to summarizing prescribing frequency and variation among both primary care practices and individual physicians, our study is also the first to date to identify some of the patient and physician characteristics associated with prescription NSAID use. Patients with hypertension, prior NSAID users, and younger patients had greater odds of prescription NSAID use. Conversely, patients with heart failure, CKD, prior opioid use, and hospitalization in the past year had reduced odds of prescription NSAID use. Our findings suggest that prescription NSAID users were generally healthier and had less severe disease than nonusers. For healthy patients with a history of hypertension, NSAIDs may be an appropriate treatment if followed closely. Consistent with other studies 24,53 of low-value care, we found that physicians who were male, international medical graduates, or further removed from medical school had greater odds of prescribing an NSAID. Physicians with these common risk factors for overuse could be the subject of future studies to understand what drives their frequent prescribing despite existing recommendations.
53,60
Rosenberg and colleagues 16 found relative stability among several low-value care services, even after release of corresponding Choosing Wisely US recommendations. In fact, they observed an increase in NSAID use of 2.0% per quarter Despite these limitations, we were able to estimate prescribing rates across Ontario and by region, practice, and individual practitioner, showing substantial variability in NSAID prescribing at all levels of the health care system. This observed variation, along with the identification of patient and physician characteristics associated with NSAID use, presents an opportunity for quality improvement, with some potential targets for any resulting interventions.
Conclusions
Among a sizable cohort of primary care visits by high-risk older adults for musculoskeletal disorders, almost 10% were followed by prescription NSAID use. No significant difference in acute safety-related outcomes was found between NSAID users and nonusers. Future studies on the optimal strategies to manage musculoskeletal pain in this patient population should be undertaken. 
